[go: up one dir, main page]

WO2008035360A3 - Novel crystalline forms of candesartan cilexetil, candesartan, tritylated candesartan and tritylated candesartan cilexetil - Google Patents

Novel crystalline forms of candesartan cilexetil, candesartan, tritylated candesartan and tritylated candesartan cilexetil Download PDF

Info

Publication number
WO2008035360A3
WO2008035360A3 PCT/IN2007/000236 IN2007000236W WO2008035360A3 WO 2008035360 A3 WO2008035360 A3 WO 2008035360A3 IN 2007000236 W IN2007000236 W IN 2007000236W WO 2008035360 A3 WO2008035360 A3 WO 2008035360A3
Authority
WO
WIPO (PCT)
Prior art keywords
candesartan
tritylated
cilexetil
novel crystalline
crystalline forms
Prior art date
Application number
PCT/IN2007/000236
Other languages
French (fr)
Other versions
WO2008035360A2 (en
Inventor
Pandurang Balwant Deshpande
Parven Kumar Luthra
Dhiraj Mohansinh Rathod
Lalitkumar Keshavlal Katariya
Himanshu Manojkumar Mehta
Original Assignee
Alembic Ltd
Pandurang Balwant Deshpande
Parven Kumar Luthra
Dhiraj Mohansinh Rathod
Lalitkumar Keshavlal Katariya
Himanshu Manojkumar Mehta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alembic Ltd, Pandurang Balwant Deshpande, Parven Kumar Luthra, Dhiraj Mohansinh Rathod, Lalitkumar Keshavlal Katariya, Himanshu Manojkumar Mehta filed Critical Alembic Ltd
Publication of WO2008035360A2 publication Critical patent/WO2008035360A2/en
Publication of WO2008035360A3 publication Critical patent/WO2008035360A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides two novel crystalline forms of candesartan cilexetil which are designated as form G and form H and a novel crystalline form of candesartan, tritylated candesartan and tritylated candesartan cilexetil and process for their preparation thereof.
PCT/IN2007/000236 2006-06-13 2007-06-12 Novel crystalline forms of candesartan cilexetil, candesartan, tritylated candesartan and tritylated candesartan cilexetil WO2008035360A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN928/MUM/2006 2006-06-13
IN928MU2006 2006-06-13

Publications (2)

Publication Number Publication Date
WO2008035360A2 WO2008035360A2 (en) 2008-03-27
WO2008035360A3 true WO2008035360A3 (en) 2008-10-16

Family

ID=39190284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2007/000236 WO2008035360A2 (en) 2006-06-13 2007-06-12 Novel crystalline forms of candesartan cilexetil, candesartan, tritylated candesartan and tritylated candesartan cilexetil

Country Status (1)

Country Link
WO (1) WO2008035360A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077941A2 (en) 2004-02-11 2005-08-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
DE102008059206A1 (en) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical dosage form containing nifedipine or nisoldipine and an angiotensin II antagonist and / or a diuretic
HUP0900376A2 (en) 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate candesartan cilexetil composition
WO2011092666A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited An improved process for the preparation of candesartan cilexetil, polymorphic forms of n-trityl candesartan and their uses thereof
CN107709313B (en) * 2015-06-05 2020-10-23 浙江华海药业股份有限公司 Method for preparing trityl candesartan
CN109627234A (en) * 2019-01-30 2019-04-16 浙江省食品药品检验研究院 A kind of candesartan cilexetil crystal and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0459136A1 (en) * 1990-04-27 1991-12-04 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
WO2004085426A1 (en) * 2003-03-27 2004-10-07 Hetero Drugs Limited Novel crystalline forms of candesartan cilexetil
WO2005077941A2 (en) * 2004-02-11 2005-08-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
WO2005123721A2 (en) * 2004-06-18 2005-12-29 Ranbaxy Laboratories Limited Amorphous and polymorphic forms of candesartan cilexetil
EP1655298A1 (en) * 2004-11-03 2006-05-10 LEK Pharmaceuticals d.d. Novel polymorph forms of candesartan cilexetil

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0459136A1 (en) * 1990-04-27 1991-12-04 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
WO2004085426A1 (en) * 2003-03-27 2004-10-07 Hetero Drugs Limited Novel crystalline forms of candesartan cilexetil
WO2005077941A2 (en) * 2004-02-11 2005-08-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
WO2005123721A2 (en) * 2004-06-18 2005-12-29 Ranbaxy Laboratories Limited Amorphous and polymorphic forms of candesartan cilexetil
EP1655298A1 (en) * 2004-11-03 2006-05-10 LEK Pharmaceuticals d.d. Novel polymorph forms of candesartan cilexetil

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRITAIN ET AL: "Polymorphism in Pharmaceutical Solids passage", POLYMORPHISM IN PHARMACEUTICAL SOLIDS, 1999, pages 235 - 238, XP002278123 *
CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1998, pages 163 - 208, XP001156954, ISSN: 0340-1022 *
FERNANDEZ, DANIEL ET AL: "Candesartan cilexetil, an antihypertensive agent containing an extended double ester chain", ACTA CRYSTALLOGRAPHICA, SECTION E: STRUCTURE REPORTS ONLINE, vol. E61, no. 2, 2005, pages O309 - O312, XP002474295 *
HIROKAZU MATSUNAGA ET AL: "Solid-state characterization of candesartan cilexetil (TCV-116): crystal structure and molecular mobility", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 47, no. 2, February 1999 (1999-02-01), pages 182 - 186, XP002957606, ISSN: 0009-2363 *

Also Published As

Publication number Publication date
WO2008035360A2 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
WO2009025876A8 (en) Crystalline forms of erlotinib hcl and formulations thereof
WO2008149345A3 (en) Tri-aryl compounds and compositions comprising the same
DK3872059T3 (en) Process for the preparation of 2,3,3,3 tetrahydrofluoropropene
WO2007127292A3 (en) Tigeycline crystalline forms and processes for preparation thereof
WO2007093627A3 (en) Biocidal composition
WO2006074951A3 (en) Orally disintegrating composition of olanzapine or donepezil
ZA200904333B (en) Process for the preparation of 6,6-Dimethyl-3-azabicyclo-[3.1.0]-hexane compounds utilizing bisulfite intermediate
WO2008021342A3 (en) Amorphous and crystalline forms of 9-hydroxy-risperidone ( paliperidone )
MX2009008660A (en) Method for the preparation of therapeutically valuable triphenylbutene derivatives.
WO2008140641A3 (en) Pure paliperidone and processes for preparing thereof
WO2008088779A3 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
WO2008083130A3 (en) Amorphous and crystalline form a of carvedilol phosphate
WO2007132354A3 (en) Process for preparing voriconazole, new polymorphic form of intermediate thereof, and uses thereof
WO2007098273A3 (en) Novel crystalline forms of armodafinil and preparation thereof
WO2008075205A3 (en) Improved process for the preparation of voriconazole
WO2008021346A3 (en) Pure paliperidone and processes for preparing thereof
WO2008035360A3 (en) Novel crystalline forms of candesartan cilexetil, candesartan, tritylated candesartan and tritylated candesartan cilexetil
WO2008137134A3 (en) Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
WO2009000533A8 (en) Novel herbicides
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
WO2010039885A3 (en) Crystalline forms of dexlansoprazole
WO2009062659A3 (en) Polymorphs of enantiopure erdosteine
WO2008094617A3 (en) Crystalline forms of deferasirox
WO2008104957A3 (en) Novel polymorphic forms of milnacipran hydrochloride
EP1996192A4 (en) Process for the preparation of 3,4-disubstituted-thiazolidin-2-ones

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07859577

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07859577

Country of ref document: EP

Kind code of ref document: A2